Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II clinical trial to assess the safety of SPK-3006 (SPK-GAA)

Trial Profile

A Phase I/II clinical trial to assess the safety of SPK-3006 (SPK-GAA)

Phase of Trial: Phase I/II

Latest Information Update: 15 Oct 2018

At a glance

  • Drugs SPK GAA (Primary)
  • Indications Glycogen storage disease type II
  • Focus Adverse reactions
  • Most Recent Events

    • 15 Oct 2018 New trial record
    • 08 Oct 2018 According to a Spark Therapeutics media release, the company plans to submit an IND application and Clinical Trial Application (CTA) to regulatory agencies and initiate a U.S. and European Union Phase I/II clinical trial of SPK-3006 in adult patients in 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top